Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is an innovative biotechnology company with a strong pipeline of gene therapy treatments for various genetic defects and diseases. They have a solid financial position with a projected market value of $1.68B and a price objective of $26 per share. The company has strategically aligned with the FDA for the resubmission of the BLA for NAVSUNLI, and their Phase 3 trials for subretinal and suprachoroidal sura-vec are on track, with expected topline results in 4Q26. They have also reported positive topline data for their DMD gene therapy and have a promising outlook for FDA approval.

Bears say

Regenxbio is a clinical-stage biotechnology company with a negative outlook due to several key factors. These include the uncertainty surrounding the success and approval of its gene therapy candidates, potential competition in the market, and potential dilution risks. Additionally, the company's projected financials do not support strong growth potential, as evidenced by its low revenue and net income figures.

REGENXBIO (RGNX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 10 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.